Evotec SE (XETRA: EVT.DE) Stock Competitors & Peer Comparison
See EVT.DE's competitors and their performance on the XETRA and across the wider stock market.
Peer Comparison Table: Drug Manufacturers - Specialty & Generic Industry
Detailed financial metrics including price, market cap, P/E ratio, and more for EVT.DE and its XETRA peers.
| Symbol | Price | Change % | Market Cap | P/E Ratio | EPS | Dividend Yield |
|---|---|---|---|---|---|---|
| EVT.DE | €3.27 | -2.56% | 581.5M | -2.98 | -€1.10 | N/A |
| MRK.DE | €138.40 | +0.33% | 60.1B | 16.48 | €8.40 | +1.59% |
| ZOE.DE | €65.68 | -1.29% | 27.5B | 11.75 | €5.59 | +2.72% |
| 5EA.DE | €20.96 | +1.53% | 10.4B | -51.11 | -€0.41 | N/A |
| DMP.DE | €39.80 | -0.87% | 2B | 14.64 | €2.72 | +2.21% |
| 2HQ0.DE | €4.07 | -1.21% | 454.6M | -7.48 | -€0.54 | N/A |
| PSG.DE | €29.00 | +0.00% | 333.9M | 17.26 | €1.68 | N/A |
| HAEK.DE | €21.40 | -1.83% | 111.5M | 11.57 | €1.85 | N/A |
| APPH.DE | €11.00 | +0.00% | 91.6M | 137.50 | €0.08 | N/A |
| 2HQ.DE | €0.68 | -5.05% | 78.9M | -0.66 | -€1.04 | N/A |
Stock Comparison
Merck KGaA (XETRA: MRK.DE)
EVT.DE vs MRK.DE Comparison August 2026
Evotec SE (XETRA: EVT.DE) plays a significant role within the Healthcare sector. Its performance on the XETRA reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EVT.DE stands at 581.5M. In comparison, MRK.DE has a market cap of 60.1B. Regarding current trading prices, EVT.DE is priced at €3.27 on the XETRA, while MRK.DE trades at €138.40.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EVT.DE currently has a P/E ratio of -2.98, whereas MRK.DE's P/E ratio is 16.48. In terms of profitability, EVT.DE's ROE is -0.26%, compared to MRK.DE's ROE of +0.08%. Regarding short-term risk, EVT.DE is more volatile compared to MRK.DE. This indicates higher risk in terms of short-term price fluctuations for EVT.DE.Check MRK.DE's competition here
Zoetis Inc. (XETRA: ZOE.DE)
EVT.DE vs ZOE.DE Comparison August 2026
Evotec SE (XETRA: EVT.DE) plays a significant role within the Healthcare sector. Its performance on the XETRA reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EVT.DE stands at 581.5M. In comparison, ZOE.DE has a market cap of 27.5B. Regarding current trading prices, EVT.DE is priced at €3.27 on the XETRA, while ZOE.DE trades at €65.68.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EVT.DE currently has a P/E ratio of -2.98, whereas ZOE.DE's P/E ratio is 11.75. In terms of profitability, EVT.DE's ROE is -0.26%, compared to ZOE.DE's ROE of +0.69%. Regarding short-term risk, EVT.DE is more volatile compared to ZOE.DE. This indicates higher risk in terms of short-term price fluctuations for EVT.DE.Check ZOE.DE's competition here
Elanco Animal Health, Inc. (XETRA: 5EA.DE)
EVT.DE vs 5EA.DE Comparison August 2026
Evotec SE (XETRA: EVT.DE) plays a significant role within the Healthcare sector. Its performance on the XETRA reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EVT.DE stands at 581.5M. In comparison, 5EA.DE has a market cap of 10.4B. Regarding current trading prices, EVT.DE is priced at €3.27 on the XETRA, while 5EA.DE trades at €20.96.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EVT.DE currently has a P/E ratio of -2.98, whereas 5EA.DE's P/E ratio is -51.11. In terms of profitability, EVT.DE's ROE is -0.26%, compared to 5EA.DE's ROE of -0.03%. Regarding short-term risk, EVT.DE is more volatile compared to 5EA.DE. This indicates higher risk in terms of short-term price fluctuations for EVT.DE.Check 5EA.DE's competition here
Dermapharm Holding SE (XETRA: DMP.DE)
EVT.DE vs DMP.DE Comparison August 2026
Evotec SE (XETRA: EVT.DE) plays a significant role within the Healthcare sector. Its performance on the XETRA reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EVT.DE stands at 581.5M. In comparison, DMP.DE has a market cap of 2B. Regarding current trading prices, EVT.DE is priced at €3.27 on the XETRA, while DMP.DE trades at €39.80.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EVT.DE currently has a P/E ratio of -2.98, whereas DMP.DE's P/E ratio is 14.64. In terms of profitability, EVT.DE's ROE is -0.26%, compared to DMP.DE's ROE of +0.21%. Regarding short-term risk, EVT.DE is more volatile compared to DMP.DE. This indicates higher risk in terms of short-term price fluctuations for EVT.DE.Check DMP.DE's competition here
Tilray Brands, Inc. (XETRA: 2HQ0.DE)
EVT.DE vs 2HQ0.DE Comparison August 2026
Evotec SE (XETRA: EVT.DE) plays a significant role within the Healthcare sector. Its performance on the XETRA reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EVT.DE stands at 581.5M. In comparison, 2HQ0.DE has a market cap of 454.6M. Regarding current trading prices, EVT.DE is priced at €3.27 on the XETRA, while 2HQ0.DE trades at €4.07.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EVT.DE currently has a P/E ratio of -2.98, whereas 2HQ0.DE's P/E ratio is -7.48. In terms of profitability, EVT.DE's ROE is -0.26%, compared to 2HQ0.DE's ROE of -0.08%. Regarding short-term risk, EVT.DE is less volatile compared to 2HQ0.DE. This indicates lower risk in terms of short-term price fluctuations for EVT.DE.Check 2HQ0.DE's competition here
PharmaSGP Holding SE (XETRA: PSG.DE)
EVT.DE vs PSG.DE Comparison August 2026
Evotec SE (XETRA: EVT.DE) plays a significant role within the Healthcare sector. Its performance on the XETRA reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EVT.DE stands at 581.5M. In comparison, PSG.DE has a market cap of 333.9M. Regarding current trading prices, EVT.DE is priced at €3.27 on the XETRA, while PSG.DE trades at €29.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EVT.DE currently has a P/E ratio of -2.98, whereas PSG.DE's P/E ratio is 17.26. In terms of profitability, EVT.DE's ROE is -0.26%, compared to PSG.DE's ROE of +0.54%. Regarding short-term risk, EVT.DE is more volatile compared to PSG.DE. This indicates higher risk in terms of short-term price fluctuations for EVT.DE.Check PSG.DE's competition here
Haemato AG (XETRA: HAEK.DE)
EVT.DE vs HAEK.DE Comparison August 2026
Evotec SE (XETRA: EVT.DE) plays a significant role within the Healthcare sector. Its performance on the XETRA reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EVT.DE stands at 581.5M. In comparison, HAEK.DE has a market cap of 111.5M. Regarding current trading prices, EVT.DE is priced at €3.27 on the XETRA, while HAEK.DE trades at €21.40.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EVT.DE currently has a P/E ratio of -2.98, whereas HAEK.DE's P/E ratio is 11.57. In terms of profitability, EVT.DE's ROE is -0.26%, compared to HAEK.DE's ROE of +0.06%. Regarding short-term risk, EVT.DE is less volatile compared to HAEK.DE. This indicates lower risk in terms of short-term price fluctuations for EVT.DE.Check HAEK.DE's competition here
Apontis Pharma AG (XETRA: APPH.DE)
EVT.DE vs APPH.DE Comparison August 2026
Evotec SE (XETRA: EVT.DE) plays a significant role within the Healthcare sector. Its performance on the XETRA reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EVT.DE stands at 581.5M. In comparison, APPH.DE has a market cap of 91.6M. Regarding current trading prices, EVT.DE is priced at €3.27 on the XETRA, while APPH.DE trades at €11.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EVT.DE currently has a P/E ratio of -2.98, whereas APPH.DE's P/E ratio is 137.50. In terms of profitability, EVT.DE's ROE is -0.26%, compared to APPH.DE's ROE of +0.02%. Regarding short-term risk, EVT.DE is more volatile compared to APPH.DE. This indicates higher risk in terms of short-term price fluctuations for EVT.DE.Check APPH.DE's competition here
Tilray Brands, Inc. (XETRA: 2HQ.DE)
EVT.DE vs 2HQ.DE Comparison August 2026
Evotec SE (XETRA: EVT.DE) plays a significant role within the Healthcare sector. Its performance on the XETRA reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EVT.DE stands at 581.5M. In comparison, 2HQ.DE has a market cap of 78.9M. Regarding current trading prices, EVT.DE is priced at €3.27 on the XETRA, while 2HQ.DE trades at €0.68.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EVT.DE currently has a P/E ratio of -2.98, whereas 2HQ.DE's P/E ratio is -0.66. In terms of profitability, EVT.DE's ROE is -0.26%, compared to 2HQ.DE's ROE of -1.15%. Regarding short-term risk, EVT.DE is less volatile compared to 2HQ.DE. This indicates lower risk in terms of short-term price fluctuations for EVT.DE.Check 2HQ.DE's competition here
Biofrontera AG (XETRA: B8F.DE)
EVT.DE vs B8F.DE Comparison August 2026
Evotec SE (XETRA: EVT.DE) plays a significant role within the Healthcare sector. Its performance on the XETRA reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EVT.DE stands at 581.5M. In comparison, B8F.DE has a market cap of 20.7M. Regarding current trading prices, EVT.DE is priced at €3.27 on the XETRA, while B8F.DE trades at €6.80.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EVT.DE currently has a P/E ratio of -2.98, whereas B8F.DE's P/E ratio is -32.40. In terms of profitability, EVT.DE's ROE is -0.26%, compared to B8F.DE's ROE of -0.02%. Regarding short-term risk, EVT.DE is less volatile compared to B8F.DE. This indicates lower risk in terms of short-term price fluctuations for EVT.DE.Check B8F.DE's competition here
SynBiotic SE (XETRA: SBX.DE)
EVT.DE vs SBX.DE Comparison August 2026
Evotec SE (XETRA: EVT.DE) plays a significant role within the Healthcare sector. Its performance on the XETRA reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EVT.DE stands at 581.5M. In comparison, SBX.DE has a market cap of 3.4M. Regarding current trading prices, EVT.DE is priced at €3.27 on the XETRA, while SBX.DE trades at €0.72.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EVT.DE currently has a P/E ratio of -2.98, whereas SBX.DE's P/E ratio is -0.29. In terms of profitability, EVT.DE's ROE is -0.26%, compared to SBX.DE's ROE of -0.55%. Regarding short-term risk, EVT.DE is less volatile compared to SBX.DE. This indicates lower risk in terms of short-term price fluctuations for EVT.DE.Check SBX.DE's competition here
Paion AG (XETRA: PA8.DE)
EVT.DE vs PA8.DE Comparison August 2026
Evotec SE (XETRA: EVT.DE) plays a significant role within the Healthcare sector. Its performance on the XETRA reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EVT.DE stands at 581.5M. In comparison, PA8.DE has a market cap of 2.7M. Regarding current trading prices, EVT.DE is priced at €3.27 on the XETRA, while PA8.DE trades at €0.36.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EVT.DE currently has a P/E ratio of -2.98, whereas PA8.DE's P/E ratio is -0.13. In terms of profitability, EVT.DE's ROE is -0.26%, compared to PA8.DE's ROE of -0.09%. Regarding short-term risk, EVT.DE is less volatile compared to PA8.DE. This indicates lower risk in terms of short-term price fluctuations for EVT.DE.Check PA8.DE's competition here
XPhyto Therapeutics Corp. (XETRA: 4XT.DE)
EVT.DE vs 4XT.DE Comparison August 2026
Evotec SE (XETRA: EVT.DE) plays a significant role within the Healthcare sector. Its performance on the XETRA reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EVT.DE stands at 581.5M. In comparison, 4XT.DE has a market cap of 0. Regarding current trading prices, EVT.DE is priced at €3.27 on the XETRA, while 4XT.DE trades at €0.37.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EVT.DE currently has a P/E ratio of -2.98, whereas 4XT.DE's P/E ratio is -2.18. In terms of profitability, EVT.DE's ROE is -0.26%, compared to 4XT.DE's ROE of -7.27%. Regarding short-term risk, EVT.DE is more volatile compared to 4XT.DE. This indicates higher risk in terms of short-term price fluctuations for EVT.DE.Check 4XT.DE's competition here
Mallinckrodt plc (XETRA: MCD.DE)
EVT.DE vs MCD.DE Comparison August 2026
Evotec SE (XETRA: EVT.DE) plays a significant role within the Healthcare sector. Its performance on the XETRA reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EVT.DE stands at 581.5M. In comparison, MCD.DE has a market cap of 0. Regarding current trading prices, EVT.DE is priced at €3.27 on the XETRA, while MCD.DE trades at €0.18.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EVT.DE currently has a P/E ratio of -2.98, whereas MCD.DE's P/E ratio is -0.02. In terms of profitability, EVT.DE's ROE is -0.26%, compared to MCD.DE's ROE of -1.69%. Regarding short-term risk, EVT.DE is less volatile compared to MCD.DE. This indicates lower risk in terms of short-term price fluctuations for EVT.DE.Check MCD.DE's competition here